Cargando…

Seven-year exclusivity and beyond for drugs of rare diseases in China

Detalles Bibliográficos
Autores principales:	Jiang, Yale, Huang, Huiyao, Zhao, Guo, Ma, Peiwen, Zhang, Liang, Wang, Shuhang, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600485/ https://www.ncbi.nlm.nih.gov/pubmed/37900168 http://dx.doi.org/10.3389/fphar.2023.1223056

Ejemplares similares

Evolution of Early-Phase Anticancer Drug Investigations in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Targeting rare tumors: new focus for clinical research in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Outcome measures of phase III anticancer drug trials in China
por: Guo, Lanwei, et al.
Publicado: (2023)

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development
por: Wang, Shuhang, et al.
Publicado: (2022)

Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States
por: Huang, Huiyao, et al.
Publicado: (2022)

Multiple Comparisons of the Efficacy and Safety for Seven Treatments in Tibia Shaft Fracture Patients
por: Li, Haibo, et al.
Publicado: (2019)

Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China
por: Liu, Peng, et al.
Publicado: (2021)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
por: Wang, Shuhang, et al.
Publicado: (2022)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022)

Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
por: Huang, Huiyao, et al.
Publicado: (2023)

Construction of a Non-Mutually Exclusive Decision Tree for Medication Recommendation of Chronic Heart Failure
por: Bai, Yongyi, et al.
Publicado: (2022)

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy
por: Wang, Shuhang, et al.
Publicado: (2021)

Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
por: Di Paolo, Antonello, et al.
Publicado: (2021)

Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
por: Feng, Jianwei, et al.
Publicado: (2022)

Drug Repurposing for Rare Diseases: A Role for Academia
por: van den Berg, Sibren, et al.
Publicado: (2021)

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders
por: Shah, Sweta, et al.
Publicado: (2021)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Yizi, et al.
Publicado: (2022)

Anxiety, Loneliness, Drug Craving, and Depression Among Substance Abusers in Sichuan Province, China
por: Chen, Xin, et al.
Publicado: (2021)

Editorial: Beyond the Pharmacology of Psychoactive Plant Medicines and Drugs: Pros and Cons of the Role of Rituals and Set and Setting
por: Gearin, Alex K., et al.
Publicado: (2021)

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
por: Wang, Shuhang, et al.
Publicado: (2022)

Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet
por: Luzzatto, Lucio, et al.
Publicado: (2022)

Research advances in treatment methods and drug development for rare diseases
por: Han, Qiaoqiao, et al.
Publicado: (2022)

Enrichment analysis of phenotypic data for drug repurposing in rare diseases
por: Ambesi-Impiombato, Alberto, et al.
Publicado: (2023)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
por: Liu, Jia, et al.
Publicado: (2023)

Detecting One-Hundred-Year Environmental Changes in Western China Using Seven-Year Repeat Photography
por: Chen, Huai, et al.
Publicado: (2011)

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach
por: Zhou, Jiawei, et al.
Publicado: (2023)

Drug and therapeutics committee interventions in managing irrational drug use and antimicrobial stewardship in China
por: Yang, Jing, et al.
Publicado: (2022)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Analysis of Suspension of Clinical Trials for Drug Registration in China
por: Su, Xian, et al.
Publicado: (2021)

Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte(®) Platform
por: Kaldjian, Eric P., et al.
Publicado: (2022)

Rational use of drugs for the elderly during the COVID-19 pandemic in China: Challenges and opportunities
por: Yin, Qingqing, et al.
Publicado: (2023)

Establishment and Optimization of Radiomics Algorithms for Prediction of KRAS Gene Mutation by Integration of NSCLC Gene Mutation Mutual Exclusion Information
por: Wang, Jingyi, et al.
Publicado: (2022)

Adverse drug reactions and correlations with drug–drug interactions: A retrospective study of reports from 2011 to 2020
por: Jiang, Huaqiao, et al.
Publicado: (2022)

The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
por: Xia, Huan, et al.
Publicado: (2020)

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China
por: Lu, Jiancheng, et al.
Publicado: (2022)

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels
por: Li, Peiwen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_64d8qveqh3crqb1qfmb4t30l39